Trials / Unknown
UnknownNCT04285294
Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 66 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Recessive dystrophic epidermolysis bullosa (RDEB) is a hereditary skin disease characterized by cutaneous and mucosa fragility. Blister formations and erosions, resulting in chronic wounds and dystrophic scars, lead development of aggressive cutaneous squamous cell carcinoma (cSCC) in young subjects. cSCC in RDEB patients are often recurrent and sometimes aggressive. Although fibrotic and inflammatory microenvironment plays an important role in the tumoral process, specific mechanisms in cSCC of RDEB patients are still unknown. Actually, the only treatment is a wide surgical excision with poor prognostic (80% of death after the first occurrence of cSCC). The objective of the study is to describe the molecular signatures in the cSCC in RDEB patients
Conditions
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2020-02-26
- Last updated
- 2020-02-26
Source: ClinicalTrials.gov record NCT04285294. Inclusion in this directory is not an endorsement.